Clinical Trials Logo

Primary Progressive Aphasia clinical trials

View clinical trials related to Primary Progressive Aphasia.

Filter by:

NCT ID: NCT02736695 Recruiting - Clinical trials for Primary Progressive Aphasia

Assessment of Hyperphosphorylated Tau PET Binding in Primary Progressive Aphasia and Frontotemporal Dementia

SLD3
Start date: July 2016
Phase: N/A
Study type: Interventional

This study is designed to learn more about overall tau burden in the brain of patients with Primary Progressive Aphasia (PPA) and Frontotemporal Dementia.

NCT ID: NCT02606422 Completed - Clinical trials for Primary Progressive Aphasia

tDCS Intervention in Primary Progressive Aphasia

Start date: April 2013
Phase: N/A
Study type: Interventional

Primary progressive aphasia (PPA) is a neurodegenerative disease that affects first and foremost language abilities. Mild cognitive impairment (MCI) is slowly progressive decline in a single domain of cognition (e.g. language) not attributable to motor or sensory loss, without impediment of social or occupational function. MCI can be an early sign of neurodegenerative disease, or can be due to normal aging. When language is the prominent affected domain in MCI, the person may later meet criteria for PPA or may progress to the clinical syndrome of Alzheimer's dementia. Spelling, naming, and working memory (e.g. repetition) are among the language abilities affected early in the course of PPA or language-centered MCI, and different variants have distinct deficits in these domains. This research project investigates the behavioral and neuromodulatory effects of high definition transcranial direct current stimulation (HD-tDCS) during language therapy in PPA participants over time. Anodal HD-tDCS targeting the left inferior frontal gyrus (IFG) administered in combination with language therapy is expected to be more beneficial when compared to language therapy alone. It will 1) improve language performance or decrease rate of decline, 2) have better-sustained effects at 2 weeks and 2 months post-treatment, and 3) produce generalization to untrained language items and some other cognitive functions. Resting-state fMRI, diffusion tensor imaging (DTI), and volumetric data are also collected to investigate changes in functional brain connectivity associated with HD-tDCS in individuals with PPA. A better understanding of the therapeutic and neuromodulatory mechanisms of HD-tDCS as an adjunct to language therapy in PPA may have a significant impact on the development of effective therapies for PPA and MCI, and may offer insight into ways of impeding neurodegeneration that may improve patients' quality of life, as well as extend their ability to work and manage their affairs.

NCT ID: NCT02541097 Completed - Clinical trials for Primary Progressive Aphasia

Preventing Language Decline in Dementia

Start date: May 2016
Phase: N/A
Study type: Interventional

This study will establish factors fundamental to the improvement in communication and quality of life for people with dementia known as primary progressive aphasia (PPA). PPA is a type of dementia in which language declines but other cognitive skills (including memory) are preserved in the first several years after the onset. This makes those in the initial stages of PPA excellent candidates for treatment and creates a window of time (2-7 years) whereby they can lead independent lives with minimal support. However, currently, no communication therapy is available to people with PPA due to the progressive nature of the disorder and lack of awareness of available options for professionals willing to treat it. Participants with PPA in our study will receive two kinds of therapy for the words they cannot recall spontaneously, and will be trained to maintain them through social interaction. The type of training will be based on the most successful interventions the investigators provided to people with PPA in our previous work. The investigators expect that successful re-learning of forgotten words and practicing them in a group setting will facilitate retention of communication skills leading to greater personal independence and increased/maintained quality of life for people with PPA. Our study represents natural combination of two novel approaches for PPA that ultimately will lead to lower demands on the health care system.

NCT ID: NCT02439853 Completed - Clinical trials for Frontotemporal Dementia

Communication Bridge Speech Therapy Research Study

Start date: March 2013
Phase: N/A
Study type: Interventional

This is a study on Internet-based video-practice speech and language therapy for persons with primary progressive aphasia (PPA), behavioral-variant frontotemporal dementia (bvFTD), or related conditions.

NCT ID: NCT01818661 Recruiting - Clinical trials for Primary Progressive Aphasia

Longitudinal Multi-Modality Imaging in Progressive Apraxia of Speech

Start date: July 1, 2018
Phase: Phase 4
Study type: Interventional

The study is designed to determine the relationship between structural and functional changes in the brain on imaging and progression of speech and language, neurological and neuropsychological features in patients with neurodegenerative apraxia of speech (AOS).

NCT ID: NCT01623284 Completed - Aphasia Clinical Trials

PiB PET Scanning in Speech and Language Based Dementias

Start date: March 2010
Phase: Phase 1
Study type: Interventional

The study is designed to determine whether there are clinical features that can be used as biomarkers to predict whether underlying Alzheimer's pathology is the cause of a speech and language based dementia. The primary hypothesis is that the proportion of patients who test positive for beta-amyloid deposition will vary across different speech and language based dementias.

NCT ID: NCT01465360 Completed - Clinical trials for Mild Cognitive Impairment

Performance of AclarusDx™, a Blood-Based Transcriptomic Test for AD, in US Patients Newly Referred to a Memory Center

Start date: November 2011
Phase: N/A
Study type: Observational

The purpose of this study is to assess the performance of AclarusDx™, an investigational blood test detecting gene expression information, and intended to help physicians in making an Alzheimer's Disease diagnosis in patients having memory impairments.

NCT ID: NCT00957710 Completed - Clinical trials for Primary Progressive Aphasia

Language Treatment for Progressive Aphasia

Start date: August 2009
Phase: N/A
Study type: Interventional

Progressive aphasia is characterized by a steady and progressive loss of language skills in the presence of relatively preserved memory, attention, and thinking. The aim of this study is to slow the progression of language decline in progressive aphasia via language therapy. The first goal of this study is to improve naming abilities of individuals with progressive aphasia. This will be accomplished by carrying out an intensive treatment program for anomia. The second goal is to evaluate whether this intense language treatment re-activates affected areas and/or connections within the language network, using functional Magnetic Resonance Imaging (to measure neural activity in specific brain regions) and Diffusion Tensor Imaging tractography (to measure the connectivity between specific brain regions). This is the first study on progressive aphasia addressing both treatment and imaging in the same patients.

NCT ID: NCT00537004 Recruiting - Clinical trials for Primary Progressive Aphasia

Language in Primary Progressive Aphasia

Start date: May 2007
Phase:
Study type: Observational

The purpose of this study is to further define the neurological and linguistic deterioration in primary progressive aphasia.